advanc
immunolog
molecular
genet
acceler
understand
genet
cellular
basi
mani
diseas
time
remark
progress
recombin
dna
technolog
enabl
develop
molecular
cellular
treatment
infecti
diseas
inherit
disord
cancer
perspect
intend
give
sampl
progress
past
ten
year
cellular
genet
immun
therapi
diseas
time
monoclon
antibodi
technolog
cellular
transplant
begun
come
age
biomedicin
innov
gene
deliveri
catalyz
nascent
field
human
gene
therapi
may
also
ultim
impact
human
health
advanc
recombin
vaccin
technolog
year
occas
landmark
celebr
fiftieth
anniversari
discoveri
structur
dna
opportun
appreci
extraordinari
accomplish
modern
biolog
discoveri
pave
way
renaiss
understand
basic
biolog
principl
begin
direct
applic
treatment
human
diseas
year
mark
anoth
anniversari
ten
year
natur
medicin
time
inform
deriv
basic
research
increasingli
found
way
clinic
practic
advanc
power
disciplin
immunolog
molecular
genet
synergist
strengthen
understand
diseas
pathogenesi
allow
us
conceiv
gener
new
therapi
past
decad
sever
technolog
thought
promis
technic
challeng
proven
tractabl
make
signific
inroad
practic
medicin
develop
monoclon
antibodi
techniqu
fusion
spleenderiv
b
cell
divid
cancer
cell
creat
antibodygener
hybridomawa
greet
enthusiasm
monoclon
antibodi
predict
profound
effect
treatment
human
diseas
inde
antibodi
quickli
becam
great
practic
use
basic
research
diagnost
analysi
least
two
decad
monoclon
antibodi
provid
fundament
insight
antigen
structur
protein
help
reveal
role
certain
protein
human
diseas
earli
promis
monoclon
antibodi
therapeut
agent
slow
materi
progress
area
hamper
number
technic
hurdl
therapeut
relev
target
difficult
identifi
cost
produc
purifi
biolog
reagent
prohibit
high
wors
still
becam
evid
firstgener
antibodi
deriv
mous
hybridoma
subject
immun
respons
limit
efficaci
durat
therapeut
effect
past
decad
seen
sever
major
breakthrough
monoclon
antibodi
therapeut
realiz
antibodi
tumor
necrosi
amelior
symptom
autoimmun
diseas
includ
rheumatoid
arthriti
crohn
diseas
catalyst
antibodi
research
inde
antibodi
provid
mean
defin
role
cytokin
immunopathogenesi
rheumatoid
arthriti
simultan
becom
therapeut
intervent
three
monoclon
antibodi
recent
evalu
licens
treatment
rheumatoid
arthriti
studi
progress
psoriasi
psoriat
arthriti
substanti
improv
product
technolog
includ
abil
make
fulli
human
monoclon
antibodi
evad
immun
respons
facilit
progress
field
effort
human
monoclon
antibodi
capit
understand
structur
immunoglobulin
gene
famili
knowledg
enabl
mous
complementaritydetermin
region
region
bind
antigen
epitop
immunoglobulin
molecul
engin
human
variableand
constantregion
framework
fig
remicad
one
three
licens
monoclon
antibodi
human
antibodi
still
elicit
immun
respons
residu
mous
complementaritydetermin
region
affect
potenc
halflif
even
human
antibodi
still
elicit
limit
undesir
immun
respons
effort
focus
develop
complet
human
monoclon
antibodi
earli
hybridoma
partner
cancer
cell
fuse
spleenderiv
b
cell
incap
support
develop
human
antibodi
varieti
technic
improv
made
possibl
gener
complet
human
therapeut
antibodi
recent
licens
antibodi
adalimumab
minim
likelihood
gener
antiimmunoglobulin
respons
among
technic
improv
epsteinbarr
virustransform
cell
line
newer
myeloma
fusion
partner
support
product
human
monoclon
antibodi
use
transgen
anim
express
human
immunoglobulin
gene
develop
recombin
technolog
screen
human
librari
phage
display
sophist
replac
strategi
minim
anim
determin
residu
monoclon
antibodi
improv
product
technolog
also
advanc
field
exampl
immunoglobulin
produc
larg
scale
mammalian
cell
select
immunoglobulin
fragment
express
bacteria
antibodi
fab
fragment
chemic
modifi
pegyl
increas
halflif
vivo
advanc
allow
manufactur
appropri
scale
decreas
expens
final
identif
monoclon
antibodi
differ
affin
specif
respect
target
antigen
led
reagent
altern
properti
addit
success
rheumatoid
arthriti
monoclon
antibodi
use
increas
success
treatment
malign
one
first
advanc
field
target
receptor
treatment
tcell
leukemia
approach
grew
basic
research
use
antibodi
defin
role
tcell
prolifer
review
ref
studi
show
tcell
signal
key
process
develop
form
cancer
develop
monoclon
antibodi
receptor
well
use
protein
fuse
toxin
provid
proof
concept
target
cellspecif
growth
factor
receptor
induc
signific
clinic
respons
approach
provid
paradigm
develop
sever
antitumor
monoclon
antibodi
therapi
includ
rituximab
herceptin
treatment
lymphoma
breast
cancer
respect
well
candid
direct
toward
differ
tumor
cell
type
number
monoclon
antibodi
develop
diseas
indic
grow
rapidli
differ
antibodi
clinic
trial
beyond
evid
contribut
cancer
therapi
recent
progress
made
treatment
allerg
diseas
asthma
target
ige
chemokin
receptor
clear
sail
antibodi
therapya
number
challeng
remain
exampl
becom
clear
individu
monoclon
antibodi
treatment
rheumatoid
arthriti
differ
kinet
side
effect
may
affect
efficaci
vivo
convent
drug
side
effect
monoclon
antibodi
must
dealt
although
like
relat
mechan
action
unknown
side
effect
often
seen
pharmacotherapi
complic
alreadi
observ
antitnf
therapi
recogniz
increas
incid
infecti
complic
particularli
reactiv
tuberculosi
occur
patient
undergo
treatment
despit
problem
monoclon
antibodi
undoubtedli
find
ever
increas
use
futur
treatment
diseas
well
valid
signal
pathway
diseas
target
convent
drug
therapi
direct
develop
sever
type
cellular
transplant
shown
progress
last
ten
year
lymphocyt
cell
transfer
malign
provid
first
indic
cellular
immunotherapi
might
prove
benefici
recognit
tumor
often
contain
lymphocyt
expand
lymphocyt
growth
factor
adopt
transfer
recipi
suggest
cellbas
immun
therapi
could
import
role
treatment
cancer
inde
earli
clinic
trial
lymphocyt
transfer
treat
melanoma
result
regress
individu
review
ref
earli
observ
prompt
intens
research
defin
immun
effector
cell
mediat
effect
identifi
target
tumor
antigen
understand
cytokin
regulatori
network
might
limit
efficaci
immun
respons
exampl
abil
cytolyt
cell
recogn
process
peptid
deriv
cellular
gene
encod
tyrosinas
melanoma
led
recognit
protect
immun
respons
often
direct
toward
tumorassoci
rather
tumorspecif
antigen
addit
varieti
immunesuppress
factor
transform
growth
fa
ligand
inhibit
protect
immun
understand
stimul
effort
overcom
impedi
effect
antitumor
immun
lymphocyt
transfer
methodolog
also
use
induc
immun
respons
deliv
recombin
gene
tlymphocyt
popul
appli
cancer
inherit
genet
diseas
infecti
diseas
discuss
detail
next
section
particularli
impress
use
antigenspecif
lymphocyt
treatment
viral
infect
includ
epsteinbarr
viru
lymphoma
cytomegaloviru
vivo
success
immun
therapi
stimul
effort
develop
cancer
immunotherapi
includ
celland
genebas
vaccin
dendrit
cell
transfer
among
promis
cellular
strategi
gener
consider
excit
intens
research
past
year
reveal
consider
complex
dendrit
cell
review
ref
differ
type
dendrit
cell
myeloid
plasmacytoid
well
differ
stage
matur
describ
scientist
also
learn
maintain
expand
cell
use
cytokin
vitro
dendrit
cell
evalu
effect
varieti
immunotherapi
disord
includ
cancer
hiv
infect
like
make
signific
contribut
futur
possibl
cellular
therapi
also
realiz
field
transplant
among
impress
advanc
recent
year
use
purifi
pancreat
togeth
specif
immun
suppress
treatment
juvenileonset
diabet
autoimmun
diseas
trigger
destruct
endogen
pancreat
earli
age
adapt
cellular
therapi
replac
insulin
physiolog
manneran
approach
thought
quit
challeng
year
agoha
shown
great
promis
besid
use
specif
immun
suppress
promot
cellular
engraft
potent
regulatori
cell
reg
cell
may
suppress
immun
activ
varieti
physiolog
set
increas
understand
mechan
action
cell
improv
method
isol
may
provid
yet
approach
cellular
therapi
autoimmun
allerg
diseas
next
frontier
cellular
transplant
lie
realm
human
stem
cell
notabl
except
bone
marrow
transplant
technolog
yet
yield
therapi
diseas
select
embryon
adult
stem
cell
popul
could
potenti
use
cell
transplant
therapi
varieti
diseas
diabet
parkinson
diseas
inherit
genet
defici
sicklecel
anemia
fig
abil
develop
embryon
stem
cell
line
success
clone
sever
anim
speci
recent
year
stimul
consider
interest
use
embryon
stem
cell
use
embryon
stem
cell
medic
practic
remain
highli
controversi
current
prematur
remain
import
area
laboratori
research
consid
therapeut
potenti
number
studi
demonstr
therapeut
potenti
stem
cell
mesenchym
stem
cell
exampl
evalu
preclin
earli
clinic
studi
myocardi
infarct
abil
limit
infarct
size
whether
aberr
stem
cell
capac
selfrenew
also
unregul
growth
control
might
desir
target
treatment
malign
anoth
intrigu
idea
signific
implic
cancer
chemotherapi
bone
marrow
transplant
alreadi
proven
success
special
commit
progenitor
hematopoiet
stem
cell
highli
effect
cellbas
therapi
progress
made
commit
adult
stem
cell
lineag
major
question
remain
address
includ
understand
plastic
adult
stem
cell
control
selfrenew
differenti
capac
commit
progenitor
delin
genet
program
lead
commit
specif
pathway
differenti
like
facilit
develop
new
therapi
character
specif
cell
type
well
use
defin
media
allow
expans
specif
homogen
cell
type
might
consider
improv
translat
clinic
gene
therapi
hold
promis
progress
molecular
genet
appli
directli
treatment
human
diseas
inherit
genet
disord
origin
consid
natur
target
therapi
consider
difficulti
arisen
target
deliveri
specif
cell
type
vivo
regul
express
recombin
gene
control
vector
immunogen
review
ref
result
gene
therapi
yet
fulfil
potenti
develop
field
may
well
parallel
monoclon
antibodi
therapi
earli
stage
appar
simpl
concept
practic
realiti
translat
idea
clinic
practic
proven
difficult
first
imagin
though
gene
therapi
may
face
greater
technic
natur
medicin
volum
number
februari
hurdl
increas
sophist
molecular
biolog
may
yet
allow
approach
make
signific
contribut
medic
therapi
first
gene
transfer
studi
pioneer
blaes
anderson
colleagu
attempt
correct
adenosin
deaminas
defici
inherit
genet
disord
patient
inabl
degrad
adenosin
caus
toxic
cell
lymphocyt
deplet
result
immunodefici
clinic
trial
patient
lymphocyt
genet
modifi
laboratori
ex
vivo
reinfus
although
longterm
mark
seen
least
one
case
chang
immun
function
observ
probabl
low
frequenc
gene
transfer
cell
appar
lack
select
expans
correct
cell
possibl
immun
gener
one
bacteri
resist
gene
neomycin
includ
posit
select
retrovir
vector
studi
earli
gene
mark
studi
suggest
recombin
gene
transfer
could
achiev
select
subpopul
cell
pioneer
trial
also
help
address
import
regulatori
concern
stimul
research
vector
deliveri
vehicl
applic
inherit
acquir
diseas
inherit
hemophilia
thought
particularli
promis
gene
therapi
target
perhap
defici
protein
factor
viii
factor
ix
circul
system
made
theori
number
cell
type
inde
preliminari
trial
demonstr
gene
transfer
express
human
factor
ix
anim
human
patient
encourag
advanc
far
treatment
inherit
sever
combin
immunodefici
scid
caus
mutat
common
growth
factor
receptor
studi
bone
marrow
cell
five
children
transduc
ex
vivo
replicationdefect
retrovir
vector
express
function
transduc
cell
engraft
back
patient
repopul
lymphoid
system
restor
immun
function
first
therapeut
outcom
gene
transfer
trial
repres
breakthrough
field
similar
approach
appli
immun
disord
without
success
howev
probabl
differ
biolog
diseas
unfortun
featur
defici
led
success
confer
unexpect
side
effect
uncontrol
prolifer
genemodifi
cell
sever
subject
possibl
relat
insert
activ
oncogen
cell
experi
underscor
need
regul
express
recombin
gene
monitor
site
integr
may
induc
inadvert
gene
activ
gene
therapi
research
grown
astound
rate
past
ten
year
today
prototyp
retrovirus
join
larg
number
differ
viral
nonvir
vector
potenti
gene
deliveri
vehicl
system
differ
properti
advantag
limit
depend
diseas
target
lentivir
vector
exampl
proven
highli
effect
achiev
stabl
gene
transfer
nondivid
cell
site
integr
genom
specif
concern
relat
inappropri
activ
neighbor
gene
arisen
adenoassoci
viru
vector
consid
less
immunogen
desir
safeti
featur
less
effici
infect
certain
nondivid
cell
carri
small
therapeut
gene
adenovir
vector
highli
effect
gene
transfer
grown
high
titer
integr
highli
immunogen
thu
desir
immunotherapi
vaccin
applic
undesir
correct
inherit
genet
disord
nake
dna
dnaliposom
complex
dnamicroparticl
complex
prove
effect
induct
immun
respons
effici
respect
dna
integr
nonvir
approach
potenti
use
vector
cancer
vaccin
date
clinic
trial
gene
therapi
initi
complet
http
wwwwileycoukgenetherapi
clinic
although
first
conceiv
approach
treat
inherit
disord
gene
therapi
trial
today
target
acquir
diseas
area
seem
like
produc
next
wave
breakthrough
though
earli
develop
progress
made
reconstitut
genemodifi
cell
hivinfect
individu
provid
intracellular
gene
product
exert
antivir
effect
vivo
far
largest
proport
gene
therapi
trial
target
cancer
focu
reflect
acut
unmet
medic
need
also
requir
therapi
popul
target
cell
local
easi
identifi
transient
express
recombin
gene
may
induc
immun
effect
persist
varieti
approach
achiev
cell
cytotox
gener
antitumor
immun
fact
direct
administr
recombin
gene
vivo
oppos
ex
vivo
modif
reinfus
cell
first
perform
cancer
immunotherapi
studi
document
express
recombin
genean
allogen
histocompat
gene
design
boost
antitumor
immunityand
gener
antitumor
immun
five
patient
local
system
tumor
regress
observ
least
one
subject
approach
current
evalu
larger
phase
efficaci
trial
anoth
cancer
gene
therapi
approach
introduct
immunomodulatori
gene
cytokin
costimulatori
molecul
includ
granulocytemacrophag
colonystimul
factor
costimulatori
molecul
malign
cell
boost
antitumor
immun
respons
case
attempt
made
replac
defect
tumor
oncogen
encod
retinoblastoma
although
deliveri
gene
product
requir
cell
technic
difficult
none
approach
yet
shown
success
phase
clinic
trial
anoth
innov
approach
treat
cancer
use
condit
replic
oncolyt
virus
adenoviru
replic
cell
contain
mutant
form
encourag
preliminari
data
report
clinic
trial
use
viru
combin
chemotherapi
induc
regress
squamou
cell
carcinoma
head
neck
remain
seen
whether
virus
infect
suffici
number
tumor
cell
avoid
immun
respons
might
otherwis
limit
durat
therapeut
effect
although
substanti
progress
made
past
decad
toward
improv
gene
deliveri
technolog
field
enter
less
exuber
phase
clearli
mani
challeng
remain
technolog
fulfil
promis
includ
target
specif
cell
popul
achiev
integr
host
genom
specif
site
affect
neighbor
gene
achiev
appropri
gene
regul
avoid
immun
detect
nevertheless
technolog
continu
improv
incorpor
new
scientif
develop
among
promis
rna
interfer
transfer
small
interf
rna
molecul
offer
opportun
alter
longterm
gene
express
vivo
way
might
minim
genotox
achiev
specif
conclus
although
technolog
improv
doubt
drive
advanc
progress
like
measur
diseasespecif
effort
invest
gene
therapi
stem
cell
technolog
like
product
posit
complex
fulli
appreci
vaccin
histor
repres
one
establish
costeffect
procedur
medicin
perhap
greatest
impact
human
health
medic
intervent
jenner
smallpox
vaccin
exampl
elimin
human
infect
variola
viru
led
erad
natur
transmit
viru
whose
mortal
exceed
million
live
last
centuri
alon
impact
vaccin
polio
influenza
vaccin
reinforc
valu
approach
recent
develop
molecular
cellular
immunolog
genet
gene
deliveri
stimul
renaiss
field
vaccin
research
addit
varieti
modifi
viral
vector
includ
poxvirus
canarypox
fowlpox
modifi
vaccinia
ankara
research
develop
novel
adenoviru
serotyp
alphavirus
adenoassoci
virus
nonvir
vector
nake
dna
use
vaccin
vector
varieti
infecti
diseas
fig
nake
dna
shown
particular
promis
varieti
differ
anim
model
infecti
diseas
includ
hiv
technolog
evalu
phase
human
clinic
trial
hiv
malaria
influenza
viru
methodolog
defin
immunogen
ration
improv
immunogen
design
greatli
improv
advanc
structur
biolog
case
hiv
exampl
xray
crystallograph
studi
protein
yield
import
inform
regard
antigen
determin
molecul
base
xray
structur
specif
ration
mutat
could
design
alter
expos
potenti
antigen
determin
definit
function
structur
helic
coiledcoil
region
viral
envelop
glycoprotein
also
reveal
highli
conserv
function
domain
may
suscept
neutral
antibodi
form
antivir
therapi
advanc
recombin
pcr
make
possibl
gener
larg
librari
immunogen
select
desir
immunolog
properti
undoubtedli
field
vaccin
technolog
benefit
sophist
advanc
genom
bioinformat
although
technolog
yet
appli
largescal
clinic
vaccin
trial
larg
number
subject
trial
import
genet
factor
determin
immun
respons
make
subject
logic
focu
investig
judici
use
genotyp
human
trial
like
allow
identif
gene
determin
respons
human
popul
inform
could
use
optim
vaccin
test
predict
efficaci
specif
human
popul
final
although
field
vaccin
histor
focus
prevent
infecti
diseas
technolog
provid
broader
base
immun
modul
patholog
respons
underli
condit
recent
studi
explor
possibl
use
vaccin
immun
intervent
treatment
neurolog
diseas
specif
alzheim
diseas
base
abil
antibodi
reduc
format
neurolog
lesion
mous
model
diseas
vaccin
approach
also
develop
prevent
atherosclerosi
gener
antibodi
cholesterol
ester
transfer
protein
cetp
cetp
inhibit
might
increas
ratio
highto
lowdens
lipoprotein
favor
lipid
profil
found
individu
specif
inherit
mutat
cetp
associ
protect
cardiovascular
diseas
specif
vaccin
strategi
also
appli
varieti
allerg
autoimmun
diseas
final
note
field
cancer
immunotherapi
shown
increas
promis
tumor
antigen
better
defin
mechan
prevent
immun
respons
malign
better
understood
better
understand
basic
molecular
lesion
deliveri
technolog
well
systemat
assess
human
immun
respons
tumor
antigen
like
yield
continu
improv
success
approach
last
sever
year
advanc
genebas
deliveri
technolog
aris
field
gene
therapi
help
revit
field
vaccin
develop
advanc
understand
number
virus
methodolog
make
recombin
gene
product
proteinand
genebas
vaccin
diversifi
improv
abil
h
r
c
l
p
e
r
p
e
c
v
e
use
continu
passag
cell
line
produc
viral
vaccin
provid
greater
consist
safeti
repres
import
technolog
improv
varieti
candid
show
promis
includ
vaccin
human
papillomaviru
herpesviru
rotaviru
advanc
clinic
test
vaccin
alon
fulfil
promis
million
live
would
save
much
needless
suffer
prevent
develop
vaccin
emerg
infecti
diseas
includ
ebola
viru
sever
acut
respiratori
syndrom
coronaviru
west
nile
viru
would
contribut
greatli
biodefens
time
would
also
profound
effect
world
health
although
consider
progress
made
major
diseas
remain
recalcitr
vaccin
aid
tuberculosi
malaria
continu
extract
major
toll
human
health
next
ten
year
confluenc
virolog
immunolog
doubt
advanc
field
help
contain
varieti
diseas
perhap
advanc
constitut
signific
progress
might
expect
come
decad
fraction
effort
realiz
potenti
million
may
owe
live
novel
medic
intervent
made
possibl
golden
age
biolog
discoveri
